文献速递肾小球疾病

耐受性树突状细胞减轻实验性自身免疫性抗髓过氧化物酶肾小球肾炎

Tolerogenic Dendritic Cells Attenuate Experimental Autoimmune Antimyeloperoxidase Glomerulonephritis.
PubMed 文献 · J Am Soc Nephrol · 2019-08-23

该研究通过用NFκB抑制剂BAY 11-7082联合髓过氧化物酶(MPO)脉冲处理骨髓细胞,生成耐受性树突状细胞(MPO/BAY DC)。在已建立抗MPO免疫或抗甲基化BSA(mBSA)免疫的小鼠中,输注MPO/BAY DC可特异性抑制抗MPO免疫和肾小球肾炎,而不影响抗mBSA免疫。机制上,MPO/BAY DC通过ICOS依赖途径诱导产生IL-10的调节性T细胞,且该效应依赖CD4+Foxp3+细胞和IL-10。

要点

  • MPO/BAY DC可减轻已建立的抗MPO肾小球肾炎,且不影响无关抗原免疫。
  • 其免疫抑制效应依赖于CD4+Foxp3+调节性T细胞和IL-10。
  • MPO/BAY DC通过ICOS依赖途径诱导IL-10+调节性T细胞。

核心结论

  • MPO/BAY DC以抗原特异性方式减轻已建立的抗MPO自身免疫和肾小球肾炎,机制为通过ICOS依赖途径诱导表达IL-10的调节性T细胞。

研究设计与样本

  • 研究用NFκB抑制剂BAY 11-7082和MPO脉冲培养骨髓细胞生成MPO/BAY DC,并输注给已建立抗MPO或抗mBSA免疫的小鼠,评估免疫应答和肾小球肾炎。

主要发现

  • MPO/BAY DC降低抗MPO免疫和肾小球肾炎,但不抑制抗mBSA免疫应答。
  • MPO/BAY DC在MPO免疫小鼠中诱导产生IL-10的调节性T细胞,不影响IL-10+ CD4+Foxp3- 1型调节性T细胞或调节性B细胞。
  • 体内清除CD4+Foxp3+细胞后,MPO/BAY DC不再抑制抗MPO免疫,表明调节性T细胞是其效应所必需。
  • 体外共培养显示MPO/BAY DC通过多条途径从CD4+Foxp3-细胞生成Foxp3+调节性T细胞,并通过ICOS诱导IL-10+调节性T细胞,后者在体内得到证实。
  • 过继转移MPO/BAY DC诱导的调节性T细胞在体内通过IL-10抑制抗MPO免疫和肾小球肾炎(使用抗IL-10受体抗体验证)。

临床怎么用

  • 提示负载自身抗原的耐受性树突状细胞可能成为抗MPO肾小球肾炎的新型抗原特异性治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Background Because of their capacity to induce antigen-specific immunosuppression, tolerogenic dendritic cells are a promising tool for treatment of autoimmune conditions, such as GN caused by autoimmunity against myeloperoxidase (MPO). METHODS: We sought to generate tolerogenic dendritic cells to suppress anti-MPO GN by culturing bone marrow cells with an NFκB inhibitor (BAY 11-7082) and exposing them to a pulse of MPO. After administering these MPO/BAY dendritic cells or saline to mice with established anti-MPO or anti-methylated BSA (mBSA) immunity, we assessed immune responses and GN. We also examined mechanisms of action of MPO/BAY dendritic cells. RESULTS: MPO/BAY dendritic cells decreased anti-MPO immunity and GN without inhibiting immune responses against mBSA; they also induced IL-10-producing regulatory T cells in MPO-immunized mice without affecting IL-10+ CD4+Foxp3- type 1 regulatory T cells or regulatory B cells. MPO/BAY dendritic cells did not inhibit anti-MPO immunity when CD4+Foxp3+ cells were depleted in vivo, showing that regulatory T cells are required for their effects. Coculture experiments with dendritic cells and CD4+Foxp3- or CD4+Foxp3+ cells showed that MPO/BAY dendritic cells generate Foxp3+ regulatory T cells from CD4+Foxp3- cells through several pathways, and induce IL-10+ regulatory T cells via inducible costimulator (ICOS), which was confirmed in vivo. Transfer of MPO/BAY dendritic cell-induced regulatory T cells in vivo, with or without anti-IL-10 receptor antibody, demonstrated that they suppress anti-MPO immunity and GN via IL-10. CONCLUSIONS: MPO/BAY dendritic cells attenuate established anti-MPO autoimmunity and GN in an antigen-specific manner through ICOS-dependent induction of IL-10-expressing regulatory T cells. This suggests that autoantigen-loaded tolerogenic dendritic cells may represent a novel antigen-specific therapeutic option for anti-MPO GN.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Odobasic D, Oudin V, Ito K, et al. Tolerogenic Dendritic Cells Attenuate Experimental Autoimmune Antimyeloperoxidase Glomerulonephritis. J Am Soc Nephrol. 2019. PMID: 31444274. doi:10.1681/ASN.2019030236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。